Taube et al. [21] reported a positive correlation between PD-L1 expression on pre-treatment tumor cells biopsied from melanoma, NSCLC, and RCC patients and objective response, as well as the occurrence of clinical benefit from nivolumab treatment. The gene discussed is CD274; the disease is renal cell carcinoma.